Vertex Pharmaceuticals (VRTX) Invested Capital (2009 - 2017)

Vertex Pharmaceuticals has reported Invested Capital for 8 years, with the latest figure at $2.3 billion in Q4 2017.

• On a quarterly basis, Invested Capital rose 32.9% year-over-year to $2.3 billion in Q4 2017; TTM through Dec 2017 was $2.3 billion, a 32.9% increase from a year earlier, with the FY2017 full-year figure at $2.3 billion, up 32.9% from the prior year.
• Invested Capital was $2.3 billion for Q4 2017 at Vertex Pharmaceuticals, up from $2.0 billion in the prior quarter.
• The five-year high for Invested Capital was $2.3 billion in Q4 2017, with the low at $1.3 billion in Q1 2015.
• Average Invested Capital over 5 years is $1.6 billion, with a median of $1.5 billion recorded in 2014.
• The sharpest annual moves came in 2015 and 2017: Invested Capital dropped 5.45% in 2015, then soared 37.5% in 2017.
• Over 5 years, Invested Capital stood at $1.4 billion in 2013, then grew by 2.55% to $1.4 billion in 2014, then decreased by 0.16% to $1.4 billion in 2015, then gained by 23.24% to $1.7 billion in 2016, then jumped by 32.9% to $2.3 billion in 2017.
• The last three Invested Capital figures came in at $2.3 billion (Q4 2017), $2.0 billion (Q3 2017), and $2.0 billion (Q2 2017), per Business Quant data.